TABLE 1.
Clinical protocols in progress using costimulatory anti–4-1BB and anti-OX40 monoclonal antibodies.
| mAbs | Target | Phase | Tumor | Combination | Protocol |
| Utomilumab | 41BB | II | HER2 + Breast cancer | Avehnnab (anti-PD-Ll) | NCT03414658 |
| Utomilumab | 41BB | I | HER2 + Breast cancer | Trasluzumab (anti-HER2) | NCT03364348 |
| Urelumab | 41BB | I | Glioblastoma | Nivolumab (anti-PDl) | NCT02658981 |
| AGEN2373 | 41BB | I | Advanced Solid Tumor | – | NCT04121676 |
| MEDI0562 | OX40 | I | Head/Neck squamous cell carcinoma Melanoma | – | NCT03336606 |
| MEDI6469 | OX40 | lb | Head/Neck squamous cell carcinoma | Surgical resection | NCT02274155 |
| MEDI6469 | OX40 | I/Ib | Metastatic colorectal cancer | Radiofrequency ablation | NCT02559024 |
| INBRX-106 | OX40 | I | Locally Advanced/Metastatic tumor | Pembrolizumab | NCT04198766 |
| PF04518600 | OX40 | I/II | Acute myeloid leukemia | Avelumab (anti-PD-Ll) Azacitidine | NCT03390296 |
| PF04518600 | OX40 | II | Metastatic kidney cancer | Axitinib (TK inhibitor) | NCT03092856 |
| PF04518600 | OX40 | II | Triple negative breast cancer | Avelumab (anti-PD-Ll) | NCT03971409 |
| PF-04518600 | OX40 | I/II | Advanced malignancies | Avelumab (antiPD-Ll) Radiation | NCT03217747 |
| INCAGN01949 | OX40 | I/II | Pancreatic cancer | VLP-encapsulated TLR9 | NCT04387071 |
| SL-279252 | OX40 | I | Advanced solid tumor/Lymphoma | Fc anti-PDl | NCT03894618 |